DXCM
HealthcareDexCom, Inc.
$67.65
+$1.11 (+1.67%)
Jan 5, 2026
Price History (1Y)
Analysis
DexCom, Inc. is a healthcare company operating within the medical devices industry. The firm has a significant scale with a market capitalization of $26.53 billion and annual revenues totaling $4.52 billion, while employing 10,200 individuals. Financially, DexCom demonstrates relatively strong profitability margins, including a gross margin of 59.0%, an operating margin of 20.1%, and a profit margin of 16.0%. The company's returns on equity (ROE) and assets (ROA) are 30.6% and 7.0%, respectively. However, the debt-to-equity ratio is substantial at 94.48, while the current ratio stands at 1.56. In terms of valuation, DexCom's price-to-earnings (P/E) ratio on a trailing-twelve-month basis is 36.97 and on a forward basis is 27.29. The company's revenue growth rate over the past year is 21.6%, while earnings growth is 109.9%. Notably, the dividend yield is not applicable, with the payout ratio at 0.0% in the AVAILABLE FACTS section.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About DexCom, Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Visit website →Key Statistics
- Market Cap
- $26.53B
- P/E Ratio
- 36.97
- 52-Week High
- $93.25
- 52-Week Low
- $54.11
- Avg Volume
- 5.81M
- Beta
- 1.48
Company Info
- Industry
- Medical Devices
- Exchange
- NMS
- Country
- United States
- Employees
- 10,200